molecules of the month


inhaled dual PI3K_,_ kinase inhibitor

Ph. II (3 mg QD) for asthma; withdrawn

from re-opt. of oral PI3K_ inhibitor

Journal of Medicinal Chemistry

AstraZeneca, Gothenburg, SE

1 min read

7. The AstraZeneca inhaled dual PI3K_,_ inhibitor AZD8154 is long-acting in the lung but has low systemic exposure and is selective, potentially avoiding the known side effects of systemic PI3K inhibition. The molecule is active in cells derived from asthmatic patients as well as in a rat model, and entered Ph. 2 trials (NCT04187508) but was withdrawn due to emerging preclinical toxicology findings.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: